Login

Deniz Altunsu

ORCID: 0000-0001-7635-3521
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
A5059866422
Research Areas
  • Cancer, Hypoxia, and Metabolism
  • Enzyme function and inhibition
  • Sarcoma Diagnosis and Treatment
  • Barrier Structure and Function Studies
  • Glioma Diagnosis and Treatment
  • Cancer Genomics and Diagnostics
  • Caveolin-1 and cellular processes
  • PI3K/AKT/mTOR signaling in cancer
  • Neurological Disease Mechanisms and Treatments

Koç University
 2022

Bahçeşehir University
 2020-2021

 Development of a Rapid and Sensitive IDH1/2 Mutation Detection Method for Glial Tumors and a Comparative Mutation Analysis of 236 Glial Tumor Samples
OPENALEX - Publications 
Timuçin Avşar Alihan Sürsal Gizem Turan Berfu Nur Yiğit Deniz Altunsu and 6 more Kutay Cantasir Gözde Duyu Ahmed B. Bayoumi Özlem Yapıcıer Melih Acar Türker Kılıç

10.1007/s40291-020-00461-y article EN Molecular Diagnosis & Therapy 2020-04-09
 Targeting the blood–brain barrier disruption in hypertension by ALK5/TGF-Β type I receptor inhibitor SB-431542 and dynamin inhibitor dynasore
OPENALEX - Publications 
Müge Atış Uğur Akcan Deniz Altunsu Ecem Ayvaz Canan Uğur Yılmaz and 5 more Deniz Sarıkaya Arzu Temizyürek Bülent Ahıshalı Hélène Girouard Mehmet Kaya

10.1016/j.brainres.2022.148071 article EN Brain Research 2022-09-01
 Development of imidazolone based angiotensin II receptor type I inhibitor small molecule as a chemotherapeutic agent for cell cycle inhibition
OPENALEX - Publications 
Timuçin Avşar Berfu Nur Yiğit Gizem Turan Deniz Altunsu Seyma Calis and 5 more Bahar Kurt Türker Kılıç M. Yavuz Ergun Serdar Durdağı Melih Acar

Cell cycle inhibitors are considered as hallmark strategy for cancer treatment due to their relatively higher selectivity and efficacy on various types in comparison cytotoxic agents. Small molecules target dividing cells G1/S, G2 or M phases of arrest eventually trigger enter apoptosis and/or inhibit tumor growth. at G2/M phase is a widely used approach proliferating cells. We report novel angiotensin II receptor type I (AT1R) antagonist that also targets CDC2 (CDK1) kinase thereby showing...

10.1080/26895293.2021.1954098 article EN cc-by All Life 2021-01-01
Coming Soon ...